1.A study on the influence of hepatic arterial embolization on blood glucose in patients with hepatoma.
Journal of the Korean Radiological Society 1991;27(6):803-806
No abstract available.
Blood Glucose*
;
Carcinoma, Hepatocellular*
;
Humans
2.Recent advance in international management of hepatocellular carcinoma.
Journal of the Korean Medical Association 2013;56(11):972-982
During the most recent decade, remarkable progress has taken place in intra-arterial therapy for hepatocellular carcinoma. Advances in knowledge of hepatic vascular anatomy and tumor blood supply have contributed to the safety and efficacy of intra-arterial therapies. Technological advances in C-arm computed tomography and microcatheter systems have improved the technical success rates for superselective or ultraselective catheterization of tumor-feeding arteries. Drug-eluting bead technology has provided the option of performing chemoembolization with less systemic exposure to anticancer drugs and a more standardized delivery. Radio-embolization with yttrium-90 microspheres has emerged as a promising option offering increased quality of life. In addition, chemoembolization plays a central role in recently developed combination therapy strategies. In this era of advanced technologies and new treatment options, efforts should be made to understand the advantages and disadvantages of new technologies and treatment strategies and to apply them properly, which may lead to better local control of tumors, better quality of life, and longer patient survival.
Arteries
;
Blood
;
Carcinoma, Hepatocellular*
;
Catheterization
;
Catheters
;
Humans
;
Microspheres
;
Quality of Life
3.A Case of Hepatic Angiomyolipoma Showing Different Uptake on F-18 FDG and C-11 Acetate PET.
Nuclear Medicine and Molecular Imaging 2008;42(3):246-248
A hepatic angiomyolipoma is a rare benign tumor mainly composed of blood vessels, smooth muscle cells and fat cells in varying proportion. Hepatic angiomyolipoma is often misdiagnosed as a hepatocellular carcinoma in preoperative imaging work-up. To date, there has been little published data describing PET findings of hepatic angiomyolipoma. We report one case of hepatic angiomyolipoma that showed a high acetate and relatively low FDG uptake on PET images.
Adipocytes
;
Angiomyolipoma
;
Blood Vessels
;
Carcinoma, Hepatocellular
;
Liver
;
Myocytes, Smooth Muscle
4.Retrospective observation of dynamic levels of serum Golgi protein 73 in patients prior to the onset of liver cancer.
Jian-guo CHEN ; Wei-zhong LU ; Yuan-rong ZHU ; Yong-hui ZHANG ; Jian-hua LU ; Tao-yang CHEN
Chinese Journal of Preventive Medicine 2013;47(8):731-735
OBJECTIVETo observe the dynamic levels of serum Golgi protein 73(GP73) in patients prior to and after the onset of liver cancer, and to explore the related factors.
METHODSFrom 2007 to 2012, a periodical screening program was carried out in a group of high risk population with positive Hepatitis B surface antigens (HBsAg) , twice a year. Their serum specimens from every screening time point were kept in Qidong Biobank until liver cancer was diagnosed. Thirty-nine patients with liver cancer were recruited for the study, each of them at least had three times of specimens collected as well as B ultrasound scan (BUS) exam results at onset of disease and within 30 months before diagnosed, amongst 6 time points. In total, there were 162 specimens collected to test GP73 by double-antibody sandwich enzyme-linked immuno-sorbent assay (ELISA). Statistical analyses of time series and differences among groups were performed by stata software 10.
RESULTSThe average value of 39 patient's GP73 at the time point of liver cancer onset was (126.77 ± 73.73) µg/L, while the values at the other five time points prior to the onset were (128.32 ± 81.18) , (129.97 ± 83.62) , (127.38 ± 80.10) , (135.52 ± 97.88) and (138.24 ± 93.58) µg/L, respectively, with no significant difference (F = 0.07, P = 0.997). No obvious changing trends of GP73 were observed among the 39 liver cancer cases at the 6 time points. All 162 samples were divided into two groups: without hepatic cirrhosis (63 samples) and with cirrhosis (99 samples) according to findings of B-ultrasonic wave; whose average GP73 values were separately (97.16 ± 51.39) and (151.20 ± 91.68) µg/L. The difference showed statistical significance (F = 18.22, P < 0.01). Furthermore, if we grouped the samples by the average value of GP73 at 130.19 µg/L, then there were only 1/14 of the subjects without hepatic cirrhosis having higher GP73 values, but 12 of the 25 subjects with hepatic cirrhosis having higher GP73 values. The difference showed statistical significance (P = 0.013). The results of Linear regression model also showed that there was no correlation between GP73 and time series (t = 0.75, P = 0.455), but significant correlation between GP73 and hepatic cirrhosis (t = 4.30, P < 0.01).
CONCLUSIONNo significant changes of the dynamic levels of GP73 could be found among the liver cancer patients within 30 months prior to the onset of disease. GP73 values of the patients with liver cancer may depend on their background of hepatic diseases; and hepatic cirrhosis might be one of the main influencing factors or confounding factors.
Biomarkers, Tumor ; blood ; Carcinoma, Hepatocellular ; blood ; Humans ; Liver Neoplasms ; blood ; Membrane Proteins ; blood ; Retrospective Studies
6.Alpha-foetoprotein: an inaccurate test for surveillance of post-treatment recurrence of hepatocellular carcinoma.
Singapore medical journal 2012;53(4):291-author reply 291
Carcinoma, Hepatocellular
;
blood
;
Female
;
Humans
;
Liver Neoplasms
;
blood
;
Male
;
alpha-Fetoproteins
;
biosynthesis
8.PIVKA-II as a Serological Marker of Hepatocellular Carcinoma.
The Korean Journal of Hepatology 2006;12(3):315-317
No abstract available.
Biological Markers/*blood
;
Carcinoma, Hepatocellular/*diagnosis
;
Humans
;
Liver Neoplasms/*diagnosis
;
Protein Precursors/*blood
;
Prothrombin
;
Tumor Markers, Biological/*blood
9.Single breath-hold MR imaging of liver.
Sun Jeong CHOI ; Seong Hee KIM ; Sun Hee KIM ; Yoo Soon CHAE ; Chun Phil CHUNG ; Yang Sook KIM
Journal of the Korean Radiological Society 1993;29(1):135-141
Single breath-hold gradient echo images with Small Tip. Angle Gradient Echo(STAGE) were evaluated in the study of liver in 16 patients(4 normal liver, 5 hepatoma, 5 cholangiocarcinoma, 1 hemangioma, 1 cavernous transformation of portal vein). We obtained one slice of gradient echo during single breath-hold at the level of pathology defined on conventional spin echo inage. Single breath-hold gradient echo images were compared with spin echo images for image quality and artifacts. Single breath-hold gradient image showed improved resolution of vascular detail and excellent contrast between lesion and adjacent normal liver in hepatoma. Cholangiocarcinoma showed decreased contrast between lesion and biliary trees but improved contrast between lesion and blood vessel. Cavernous transformation of porta vein was noted as tortuous vessel of high signal intensity. Single breath-hold gradient echo scan increased vascular artifact, but decreased respiratory artifact leading to improved image quality. Single breath-hold technique can reduce can reduce imaging time and improve image quality and may be used as complementary method to the spin echo scan.
Artifacts
;
Blood Vessels
;
Carcinoma, Hepatocellular
;
Cholangiocarcinoma
;
Hemangioma
;
Liver*
;
Magnetic Resonance Imaging*
;
Methods
;
Pathology
;
Trees
;
Veins
10.Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinomas.
Seong Woo HONG ; Hee Jung WANG ; Yun Mi JIN ; Wook Hwan KIM ; Eu Young SO ; Myung Wook KIM
Journal of the Korean Surgical Society 1999;57(1):81-85
BACKGROUND: A tumor must continuously stimulate the growth of new capillary blood vessels for the tumor itself to grow and metastasize. Vascular endothelial growth factor (VEGF) promotes vascular permeability and endothelial cell growth. A hepatocellular carcinoma (HCC) is a typical hypervascular tumor. METHODS: We evaluated the expression of VEGF in 36 cases of HCC by using immunohistochemical staining in order to define its prognostic value. RESULTS: The expression rate of VEGF was 44.4% (16/36) in tumor cells and 0% (0/36) in non- tumorous liver parenchyme. VEGF expression did not correlate with any clinicopathological characteristics. And patients with expression of VEGF in tumor cells had no survival difference in comparison to those without VEGF expression. CONCLUSIONS: These results suggest that the expression of VEGF in HCC cells by itself may not be a significant factor in the prognosis of HCC.
Blood Vessels
;
Capillaries
;
Capillary Permeability
;
Carcinoma, Hepatocellular*
;
Endothelial Cells
;
Humans
;
Liver
;
Prognosis
;
Vascular Endothelial Growth Factor A*